Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 250 mg - levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin  injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). levofloxacin tablets are indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levofloxacin tablets are indicated for the treatment of community-acquired pneumonia due to methicillin-sus

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - carisoprodol 200 mg - carisoprodol, aspirin and codeine phosphate tablets, usp are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses (seewarnings ), reserve carisoprodol, aspirin and codeine phosphate tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia carisoprodol, aspirin and codeine phosphate tablets,usp should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration (see dosage and administration ). carisoprodol, aspirin and codeine phosphate tablets are contraindicated for: - all children

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - lamotrigine (unii: u3h27498ks) (lamotrigine - unii:u3h27498ks) - lamotrigine 5 mg - adjunctive therapy lamotrigine tablets for oral suspension are indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older: - partial-onset seizures. - primary generalized tonic-clonic (pgtc) seizures. - generalized seizures of lennox-gastaut syndrome. monotherapy lamotrigine tablets for oral suspension are indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (aed). safety and effectiveness of lamotrigine tablets for oral suspension have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from aeds other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant aeds. lamotrigine tablets for oral suspension are indicated for the maintenance treatment of bipolar i disorder to

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - trihexyphenidyl hydrochloride (unii: ao61g82577) (trihexyphenidyl - unii:6rc5v8b7po) - trihexyphenidyl hydrochloride 2 mg - trihexyphenidyl hcl is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). it is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones. trihexyphenidyl hcl is contraindicated in patients with hypersensitivity to trihexyphenidyl hcl or to any of the tablet ingredients. trihexyphenidyl hcl is also contraindicated in patients with narrow angle glaucoma. blindness after long-term use due to narrow angle glaucoma has been reported. although trihexyphenidyl hcl is not classified as a controlled substance, the possibility of abuse should be borne in mind due to its stimulant and euphoriant properties.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - dipyridamole (unii: 64alc7f90c) (dipyridamole - unii:64alc7f90c) - dipyridamole 25 mg - dipyridamole tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement. hypersensitivity to dipyridamole and any of the other components.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals inc. - hydroxyzine pamoate (unii: m20215mufr) (hydroxyzine - unii:30s50ym8og) - hydroxyzine hydrochloride 25 mg - for symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. as a sedative when used as premedication and following general anesthesia, hydroxyzine may potentiate meperidine (demerol®) and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. atropine and other belladonna alkaloids are not affected by the drug. hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. the effectiveness of hydroxyzine as an antianxiety agent for long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should reassess periodically the usefulness of the drug for the individual patient. hydroxyzine, when ad

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc - flunisolide (unii: qk4dys664x) (flunisolide anhydrous - unii:78m02aa8kf) - flunisolide 0.25 mg in 1 ml - flunisolide nasal solution is indicated for the treatment of the nasal symptoms of seasonal or perennial rhinitis. flunisolide nasal solution should not be used in the presence of untreated localized infection involving the nasal mucosa. hypersensitivity to any of the ingredients.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - abacavir 20 mg in 1 ml - abacavir oral solution, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection. abacavir oral solution is contraindicated in patients: - who have the hla-b*5701 allele [see warnings and precautions (5.1)] . - with prior hypersensitivity reaction to abacavir [see warnings and precautions (5.1)]. - with moderate or severe hepatic impairment [see use in specific populations (8.6)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data). the apr uses the macd

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - alprazolam (unii: yu55mq3izy) (alprazolam - unii:yu55mq3izy) - alprazolam 0.25 mg - alprazolam tablets, usp are indicated for the management of anxiety disorder (a condition corresponding most closely to the apa diagnostic and statistical manual [dsm-­iii-r] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry (apprehensive expectation) about two or more life circumstances, for a period of 6 months or longer, during which the person has been bothered more days than not by these concerns. at least 6 of the following 18 symptoms are often present in these patients: motor tension (trembling, twitching, or feeling shaky; muscle tension, aches, or soreness; restlessness; easy fatigability); autonomic hyperactivity (shortness of breath or smothering sensations; palpitations or accelerated heart rate; sweating, or cold clammy hands; dry mouth; dizz

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease. albuterol tablets are contraindicated in patients with a history of hypersensitivity to albuterol, or any of their components.